Toleranzia
0,52 SEK -1,89%Vær den første som følger denne virksomhed
Toleranzia is a research company focused on the development of drug candidates for the treatment of autoimmune diseases. The company has developed a platform technology focused on the muscular disease myasthenia gravis. In addition, the technology has been used in other areas such as diabetes and multiple sclerosis. Research collaboration is done together with external partners within the field. The head office is based in Gothenburg.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
TOL
Daglig lav / høj pris
0,5 / 0,54
SEK
Markedsværdi
102,48 mio. SEK
Aktieomsætning
37,16 t SEK
Volumen
73 t
Finanskalender
Delårsrapport
20.05.2024
Generalforsamling
19.06.2024
Delårsrapport
23.08.2024
Delårsrapport
24.10.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Flerie Invest AB | 57,1 % | 57,1 % |
Avanza Pension | 3,5 % | 3,5 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Toleranzia AB – Year-End Report 2023
Toleranzia successfully completes GLP toxicology study of TOL2
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools